The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors
Open accessAbstract
We read with great interest the articles by Kostine et al 1 (and subsequent correspondence by Arnaud et al 2) and by Belkhir et al. 3 The prognosis of various cancer types has dramatically improved since the advent of immune checkpoint inhibitors (ICIs). Yet, ICI therapy is associated with frequent and potentially organ or life-threatening immune-related adverse events (irAEs), generally mimicking autoimmune or inflammatory conditions.4 Rheumatic disorders have been reported in this setting, mainly rheumatoid arthritis, polymyalgia rheumatica and systemic lupus erythematosus.1–3 Vasculitis seems to occur more seldom, with predominantly medium-vessel to large-vessel involvement.5 Here, we report on a patient with eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) following treatment with ICI for a stage IV melanoma. A 34-year-old non-smoking female patient with stage IV melanoma was treated with ipilimumab (a monoclonal antibody targeting the cytotoxic T–lymphocyte associated antigen …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Multiple recent reports of Eo-irAEs like eosinophilic fasciitis or eosinophilic granulomatosis with polyangiitis suggest that topical or low-dose oral corticosteroids, with or without CS-sparing treatments, can give excellent results.
“multiple recent reports of Eo-irAEs like eosinophilic fasciitis27-30 or eosinophilic granulomatosis with polyangiitis31 suggest that topical or low-dose oral corticosteroids, with or without CS-sparing treatments, can give excellent results.”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [31]
The EGPA case report describes rapid improvement after inhaled corticosteroids and a long-acting beta-agonist, and later treatment with inhaled therapy and an intra-articular corticosteroid injection (case description; page unavailable). It does not report treatment with topical or low-dose oral corticosteroids or a corticosteroid-sparing drug. Symptoms also worsened despite continued inhaled therapy when nivolumab was reintroduced, so the claimed excellent results from the stated regimens are not established by this case. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Masi, A. T., Hunder, G. G., Lie, J. T., Michel, B. A., Bloch, D. A., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330806 · Cited by 2,212
Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318
Self-citationKostine, M., Rouxel, L., Barnetche, T., Veillon, R., Martin, F., Dutriaux, C., Dousset, L., Pham‐Ledard, A., Prey, S., Beylot-Barry, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212257 · Cited by 310
Belkhir, R., Burel, S. L., Dunogeant, L., Marabelle, A., Hollebecque, A., Besse, B., Leary, A. F., Voisin, A.-L., Pontoizeau, C., Coutte, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211216 · Cited by 245
Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
Cottin, V., Bel, E., Bottero, P., Dalhoff, K., Humbert, M., Lazor, R., Sinico, R. A., Sivasothy, P., Wechsler, M. E., Groh, M., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.09.018 · Cited by 175
Self-citationAutoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
Tocut, M., Brenner, R. M., & Zandman‐Goddard, G. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.010 · Cited by 108
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
Bernard-Tessier, A., Jeanville, P., Champiat, S., Lazarovici, J., Voisin, A.-L., Mateus, C., Lambotte, O., Annereau, M., & Michot, J.-M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.017 · Cited by 78
Checkpoint inhibitor-associated immune arthritis
Arnaud, L., Lebrun‐Vignes, B., & Salem, J. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213470 · Cited by 35
Flagged first, then by citations
Cited by
Sorted by citations
Scanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722022 · Cited by 59
Self-citation
Metadata
- Authors
- Roger, A., Groh, M., Lorillon, G., Le Pendu, C., Maillet, J., Arangalage, D., Tazi, A., Lebbe, C., Baroudjian, B., & Delyon, J.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Inserm (FR)
- Corresponding author
- Delyon, Julie
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 78
- Issue
- 8
- Pages
- e82-e83
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2808957918
- Semantic Scholar
- 6e3c140e1f3ee94c2c7bea06ab41f9291d26d831
- Cited by
- 39
- References
- 10
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 9 · 2020: 7 · 2019: 5
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Keywords
- eosinophilic granulomatosis with polyangiitis, immune checkpoint inhibitors, nivolumab, drug-induced vasculitis, eosinophil count, metastatic melanoma
- MeSH terms
- Arthritis, Rheumatoid, Humans, Polymyalgia Rheumatica, Giant Cell Arteritis, Granulomatosis with Polyangiitis, Churg-Strauss Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
